Table 4.
Pain during acute inflammation: skin.
| Drug | Dose | Route | Reference |
|---|---|---|---|
| Capsaicin | |||
| Antagonists | |||
| MK-801 | 0.1–1.0 mM, 50 μl | i.pl. | Jin et al., 2009 |
| CNQX | 1–5 mM, 50 μl | i.pl. | Jin et al., 2009 |
| CPCCOEt | 5 mM, 50 μl | i.pl. | Jin et al., 2009 |
| MPEP | 30 mM, 50 μl | i.pl. | Jin et al., 2009 |
| Carrageenan | |||
| Antagonists | |||
| MK-801 | 200 μM (10 nmol/50 μl) | i.pl. | Jackson et al., 1995 |
| CNQX | 2 mM (100 nmol/50 μl) | i.pl. | Jackson et al., 1995 |
| MPEP | 3–30 mM (0.03–0.3 μmol/10 μl) | i.pl. | Walker et al., 2001 |
| NA-3,4,-DCM | 0.85–8.52 μmol/kg | i.p. | Quintao et al., 2010 |
| Prostaglandin and interleukins | |||
| Agonists | |||
| APDC | 11 μM (20 ng/10 μl) | i.pl. | Yang & Gereau, 2002 |
| APDC | 46 μM (200 ng/25 μl) | s.c., orofacial | Ahn et al., 2005; Jung et al., 2006 |
| DCG4 | 39 μM (200 ng/25 μl) | s.c., orofacial | Ahn et al., 2005 |
| Antagonists | |||
| AP-7 | 240 mg/kg | s.c. | Follenfant & Nakamura-Craig, 1992 |
| DNQX | 80 pg/kg | s.c. | Follenfant & Nakamura-Craig, 1992 |
| LY341495 | 57 nM (0.2 ng/10 μl) | i.pl. | Yang & Gereau, 2002 |
| DNQX | 1 mM, 20 μl | s.c., orofacial | Ahn et al., 2004 |
| CPCCOEt | 0.65 or 6.5 mM (4 or 40 μg/25 μl) | s.c., orofacial | Ahn et al., 2005 |
| LY367385 | 1.9 or 19 mM (10 or 100 μg/25 μl) | s.c., orofacial | Ahn et al., 2005 |
| MPEP | 1.2 or 12 mM (7 or 70 μg/25 μl) | s.c., orofacial | Ahn et al., 2005 |
| SIB1893 | 2 or 20 mM (10 or 100 μg/25 μl) | s.c., orofacial | Ahn et al., 2005 |
| Endothelin-1 (ET-1) | |||
| Antagonists | |||
| MK-801 | 100 μM, 10 μl | i.pl. | Khodorova et al., 2009 |
| D-AP-5 | 5 mM, 10 μl | i.pl. | Khodorova et al., 2009 |
| Bee (Apis mellifera) venom | |||
| Agonists | |||
| APDC | 2–100 μM (0.1–5 nmol/50 μl) | i.pl. | Chen et al., 2010 |
| Antagonists | |||
| MK 801 | 0.01 mg/kg | i.p. | Chen & Chen, 2000 |
| AIDA | 10–500 μM (0.5–25 nmol/50 μl) | i.pl. | Chen et al., 2010 |
| LY341495 | 4 μM (0.2 nmol/50 μl) | i.pl. | Chen et al., 2010 |
| L-AP4 | 2–200 μM (0.1–10 nmol/50 μl) | i.pl. | Chen et al., 2010 |
| MSOP | 200 μM (10 nmol/50 μl) | i.pl. | Chen et al., 2010 |
| AP-5 | 10 mM, 50 μl | Muscle, injection | You et al., 2002 |
| Phoneutria nigriventer spider venom | |||
| Antagonists | |||
| MK-801 | 1 μM (100 pmol/100 μl) | i.pl. | Zanchet & Cury, 2003 |
| CNQX | 1 mM (100 nmol/100 μl) | i.pl. | Zanchet & Cury, 2003 |
| AP5 | 0.4 μM (40 pmol/100 μl) | i.pl. | Zanchet & Cury, 2003 |
| Formalin i.pl. | |||
| Agonists | |||
| S-DHPG | 1.0 μm, 20 μl | Zhou et al., 2001 | |
| Antagonists | |||
| MK-801 | 0.1–100 μM, 30 μl | i.pl. | Davidson et al., 1997 |
| CNQX | 1–1000 μM, 30 μl | i.pl. | Davidson et al., 1997 |
| Dextrorphan | 0.1–10 μM, 40 μl | i.pl. | Davidson & Carlton, 1998 |
| Memantine, ketamine | 1–10 μM, 40 μl | i.pl. | Davidson & Carlton, 1998 |
| AIDA | 0.4–40 μM, 20 μl | i.pl. | Zhou et al., 2001 |
| MPEP | 3 mM (30 nmol/10 μl) | i.pl. — mice | Bhave et al., 2001 |
| CPCCOEt | 10 mM (100 nmol/10 μl) | i.pl. — mice | Bhave et al., 2001 |
| NA-3,4,-DCM | 14–140 mM (0.28–2.8 μmol/20 μl) | i.pl. — mice | Quintao et al., 2010 |